1. Levels of serum inhibitor of plasminogen activation, anti-plasmin and plasminogen activator were measured in normal subjects and patients with active glomerulonephritis and chronic renal failure.
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and it has been suggested that the presence of fibrin in glomeruli has a role in the development or persistence of renal damage in man (Vassalli & McCluskey, 1965) .
In this study two natural inhibitors of the fibrinolytic system, the serum inhibitor of plasminogen activation and anti-plasmin, were assayed in groups of patients, one with active glomerulonephritis and one with chronic renal failure, to determine whether inhibition of fibrinolysis might contribute, as does EACA in experimental nephritis, to persistence of fibrin deposits in human renal disease and thus, by facilitating their organization, allow the perpetuation of glomerular damage.
M E T H O D S
Inhibitor of plasminogen activation in serum was assayed in a standard clot-lysis system (Bennett, 1967) . Serum was obtained by centrifugation of blood obtained by venepuncture and allowed to clot in a glass tube at room temperature for 60 min; after separation it was stored at -20" until tested. To 0.5 ml serum at 4" were added serially 0-2 ml urokinase (Leo Pharmaceuticals Ltd.) 400 Ploug units/ml, 0.2 ml fibrinogen and plasminogen solution (Fraction I, Armour Pharmaceutical Co.) 1 g/100 ml in phosphate buffer pH 7.4, and 0.1 ml thrombin (Topical thrombin, Parke-Davis Co. Ltd.) 10 N.I.H. units/ml. The tubes were transferred to a water-bath at 37". The interval between the addition of urokinase and lysis of the fibrin, as indicated by a rise to the surface of the bubbles trapped within the fibrin clot, was noted. A linear relationship exists over a wide range between the lysis time of this clot system and the activator content when these are plotted on log/log paper. A standard curve was prepared by replacing the serum in the clot system by a series of dilutions of EACA and the inhibitory activity of each serum sample was read from the standard curve and expressed in units, one unit being equivalent to that produced by a 1 0 -3~ solution of EACA.
Anti-plasmin activity was measured in oxalated plasma (2 mg oxalate/ml blood) by the technique of Sherry, Lindemeyer, Fletcher & Alkjaersig (1959b) , using plasmin spontaneously activated in 50% glycerol at 30" and pH 7.6. Results are expressed as % inhibition of the standard plasmin preparation. Plasminogen used to prepare the plasmin was obtained from Kabi Pharmaceuticals Ltd., Sweden.
Plasminogen activator was assessed by performing euglobulin clot-lysis times by the method of Nilsson & Olow (1962) . Results are expressed by plotting the values logarithmically against units of fibrinolytic activity (Sherry et al., 1959b) , 10 units being arbitrarily equated with a lysis time of 50 min. Times of over 500 min were assigned a value of 1 unit for purposes of calculation.
Serum proteins were measured by the biuret method of Reinhold (1953) . The serum protein fractions were estimated after electrophoresis of 2 pl serum on cellulose acetate strips and staining with Ponceau S, using a Chromoscan recording and integrating densimeter. Reproducibility studies using triplicate runs on 10 sera gave maximal variations from the mean of f 7 % for a,-globulin and normal values of the a,-globulin fraction lay within the range 0.43-0.57 g/100 ml. Serum urea was determined by the method of Marsh, Fingerhut & Kirsch (1957) . This method employs a carbamido diacetyl reaction and is modified for use in a Technicon AutoAnalyser. For normal subjects levels lay between 15 and 40 mg/100 ml.
Patients
Thirteen subjects with acute or subacute nephritis were studied. Nine had renal biopsies carried out during the course of clinical investigation. None had severe nitrogen retention at the time of observation. Fourteen subjects with chronic renal disease and severe nitrogen retention were studied. Biopsy studies were not performed on these patients. Details of the individual patients in the two groups are included in Tables 1 and 2 .
Normal values
The level of fibrinolytic inhibitors were measured in thirteen healthy volunteers aged between 20 and 75 years. All were free from symptoms of chronic and intercurrent disease and had a blood sedimentation rate (Westergren) in the normal range (Hilder & Gunz, 1964) . Control activator levels were obtained from patients convalescent from a variety of minor disorders which have been found not to affect fibrinolytic activity. All had been at rest in bed for at least 12 h because of the effect of exercise on plasminogen activator levels (Bennett, Ogston & Ogston, 1968) .
RESULTS
Patients with active glomerulonephritis had high levels of a,-globulin (mean = 1.55 g/100 ml); several showed slightly elevated serum urea, levels lying between 15 and 53 mg/100 ml (mean 35.8 mg/100 ml). Urea levels in patients with chronic renal failure ranged from 68 to 650 mg/lOO ml.
The inhibitor and plasminogen activator levels of the individual patients with renal disease appear in Tables 1 and 2 . There was gross elevation of the serum inhibitor of plasminogen activation in all the patients with active glomerulonephritis. In four subjects, studied at intervals of 5 weeks to 2 years after the acute disease, recovery from glomerulonephritis was associated with a fall in the inhibitor level (Table 3) . For example, the inhibitor of activation fell from over 10 units to 4.2 units over a period of 5 weeks in one patient when, under the influence of steroid therapy, loss of oedema and disappearance of proteinuria had occurred. The level of this inhibitor was also elevated in patients with chronic renal failure though the change was less striking than in the group with glomerulonephritis. The difference in the mean level of inhibitor of plasminogen activation of both groups from that of the normal subjects was significant (P<O.Ol in each case).
Anti-plasmin levels in patients with active glomerulonephritis were much higher than those of the control subjects and the difference between the means was significant (P<O*Ol). The plasma of patients with chronic renal failure had a less marked increase in anti-plasmin activity but the difference of the mean from that of the control group reached the 5 % level of significance.
Plasminogen activator levels were significantly reduced in patients with chronic renal failure (mean 1.7 units, P<O*OOl). The reduction in activator level in patients with active glomerulonephritis was much less marked (mean 3.4 units, P<0-05).
DISCUSSION
The human fibrinolytic enzyme system comprises the plasma P-globulin, plasminogen, which on activation is converted to plasmin, a protease of broad specificity (Sherry, Fletcher & Alkjaersig, 1959a) . Small quantities of a plasminogen activator circulate normally in human blood; activators of plasminogen are also present in most tissues including the kidney. It is probable that the activity of the system is controlled by inhibitors. Natural inhibitors of fibrinolysis fall into two main groups, those acting on plasmin, principally a,-macroglobulin and a,-antitrypsin Norman & Hill, 1958; Ganrot, 1967) , and those which inhibit the activation of plasminogen. The latter type of inhibitor may be of considerable physiological importance in view of the central role played by activator in fibrinolysis (Sherry 
of control
(n = 13 (n = 13 (n = 25 subjects SD = 0.6) SD = 6.5) SD = 1.5) * Diagnosis of glomerulonephritis confirmed by histological appearances of needle biopsy sample. et al., 1959a); little is known of their properties, however, and their existence has been disputed since an assay which measures the quantity of plasmin formed in the presence of activator may be influenced not only by inhibitors of activation but also by the anti-plasmin activity of the test plasma or serum. The serum inhibitor of plasminogen activation measured in this study differs from anti-plasmin in several important properties (Bennett, 1967 (Bennett, , 1970 . It is temperature-labile, the inhibitory activity declining rapidly at 37" ; it develops during the process of spontaneous blood coagulation or thrombus formation in recalcified blood in an artificial circulation; and it requires sodium ions to function. These properties distinguish it from anti-plasmin and, in addition, there was no significant correlation "etween the two types of inhibitory activity in seventy normal subjects (Bennett, 1967) . Animal studies indicate that fibrin is deposited in glomeruli in experimental nephritis. Impaired renal function and histological glomerular changes follow intravenous injection of agents causing fibrin deposition within glomeruli (Graeff, Mitchell & Beller, 1968) . These include thrombin (Lee, 1962 ; Margaretten, Csavossy & McKay, 1967) , sodium polyethanol sulphonate (Vassalli et al., 1963; Humair et al., 1969b) , E. coli endotoxin (Beller & Graeff, 1967) , antigen-antibody complexes (Humair et al., 1969b) , thromboplastin (Vassalli et al., 1963) and nephrotoxic serum (Vassalli & McCluskey, 1964a , 1964b . Fibrin deposition is thought to play an important role in endothelial cell proliferation, crescent formation and glomerular sclerosis (Vassalli & McCluskey, 1965; Briggs et al., 1969) . Pretreatment with heparin, coumarin derivatives or the plasminogen activator, urokinase, can to a large extent prevent glomerular changes. Urokinase, when administered after fibrin deposition, can partially reverse this process (Vassalli & McCluskey, 1964a , 1964b Halpern, Milliez, Lagrue, Fray & Morard, 1965; Humair, Kwaan & Potter, 1969a) .
Similar glomerular changes in human nephritis may also be due to fibrin (Vassalli & McCluskey, 1965) , but the factor initiating its deposition is unknown. In endotoxin-induced nephritis it has been suggested that endotoxin operates by activating Factor XI1 (Hageman Factor) (Thomas, Wessler & Reimer, 1962; Rodriguez-Erdman, 1964) ; endotoxin is also known to influence platelet activity (Des Prez, Horowitz & Hook, 1961; Horowitz, Des Prez & Hook, 1962) . Fibrin deposition alone, however, may not cause irreversible renal damage: it has been shown that glomerular fibrin deposits produced in rats by infusion of thrombin (Margaretten et al., 1964 (Margaretten et al., , 1967 and rabbits (Beller, Mitchell & Gorstein, 1967) , or of endotoxin (Beller & Graeff, 1967) , disappeared within a few hours of the end of the infusion as a result of the action of the fibrinolytic enzyme system (Margaretten et al., 1967) . If fibrin deposition was induced in presence of circulating EACA, fibrin deposits persisted and irreversible renal damage ensued (Margaretten et al., 1964) . In similar experiments in which the inhibitor level was allowed to decline, fibrin disappeared from glomeruli when EACA was no longer detectable in the tissues .
Several abnormalities in the fibrinolytic system have been observed in human renal disease. These include reduced plasma activator and plasminogen levels, and raised 'plasma urokinase resistance' in a proportion of patients with some types of renal disorder (Edward, Young & MacLeod, 1964; McNicol, Barakat & Douglas, 1965) , but a consistent pattern to account for abnormally depressed fibrinolytic activity has failed to emerge. Maggiore, Jovanovic & Baldini (1 969) who carried out serial studies on children with acute post-streptococcal nephritis, observed increased blood fibrinolytic activity in the early stages of the disease, and suggested that this was probably responsible for removal of glomerular fibrin. The plasma fibrinogen level is frequently raised in patients with renal disease (Edward et al., 1964; McNicol et al., 1965; Takeda & Chen, 1967) , but hyperfibrinogenaemia alone is insufficient to account for production or persistence of fibrin deposits.
In this study, patients with active glomerulonephritis all had grossly elevated levels of inhibitor of plasminogen activation present in the serum. The characteristics of this inhibitor, its development during or concurrently with coagulation and the decline of its activity over a period of hours at body temperature, suggest that it may protect newly formed fibrin from lysis. Local release of this inhibitor during formation of fibrin deposits might ensure their persistence in a manner similar to the effect of EACA in animal studies. Organization of these deposits could then perpetuate renal damage. The return to normal of inhibitor levels in patients making a good recovery is in accord with this concept. Antiplasmin activity also was significantly elevated in patients with active glomerulonephritis. The direct relevance of this finding to persistence of fibrin is not clear, if the central role of activator, rather than plasmin, in the development of fibrinolytic activity is accepted. Raised anti-plasmin levels might, however, contribute in part to persistence of fibrin.
Patients with chronic renal disease had significantly increased levels of both inhibitor of plasminogen activation and anti-plasmin though these changes were less striking than in the group with active nephritis. Fibrin has been demonstrated in the glomeruli of patients with chronic renal failure, but interest in the fibrinolytic enzyme system in such patients has centred on its possible role in development of fibrinous exudates which occur on serous surfaces in severe uraemia (MacLeod, Stalker 8z Ogston, 1962; Edward et al., 1964; McNicol et al., 1965) . The marked depression of plasma activator and reduced tissue fibrinolytic activity noted in these studies together with elevated inhibitor levels may clearly contribute to the development of fibrinous exudates. These exudates are not a feature of active nephritis in spite of the very high inhibitor levels observed in this study. However, though subjects with active glomerulonephritis had gross elevation of inhibitor of plasminogen activation and marked increase of anti-plasmin activity, most had plasma activator levels just within the normal range. In contrast, patients with chronic renal failure who showed only moderate elevation of the two inhibitors had marked reduction of plasma activator levels. It seems possible that tissue activator levels may also differ considerably in the two conditions and as fibrinolytic activity represents a balance between activators and inhibitors, the relative quantities of each, together with the amounts of locally present tissue activator, may determine not only the development but also the sites of fibrin persistence in the different conditions.
